Key facts, as of
As of October 10, 2026, Novo Nordisk A/S (NVO) trades at $38.64, down 34.2% over the past year. Its 52-week range runs from $35.12 to $64.16; the price is 39.8% below that high. It is 73.9% below its all-time high of $148.15, reached in June 2024. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +130.3%, against +312.9% for the S&P 500 (SPY). It sits 14.9% below its 200-day average of $45.40, the usual sign of a long-term downtrend. Its 30-day volatility is 34.6% annualized, which we rate high risk. It has a trailing P/E of 9.4 and a dividend yield of 4.65%.
Cite: Portfolio Terminal, "Novo Nordisk A/S (NVO) stock analysis", 2026-10-10. https://portfolio-terminal.com/analyse/nvo
Where it trades today
trading 12% of the way up its 52-week range
How the price has moved
How far it is from its record
Novo Nordisk A/S (NVO) is 73.9% below its all-time high of $148.15, reached in June 2024. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +130.3%, against +312.9% for the S&P 500 (SPY).
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- NVO trades at 9.4x earnings versus 22.0x for the sector, which means the rerating case depends on proving the discount is too harsh.
- Recent realized volatility is running around 34.6%, above the sector norm of 22.0%, so position sizing matters more than usual.
- NVO remains in a bearish short-term trend and sits 39.8% below its high, which raises the bar for any thesis that depends on fast multiple expansion.
Portfolio Use Case
- NVO is more relevant for investors who want some income support alongside price appreciation, not just pure growth exposure.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- A recovery in price alone would not be enough to improve the view; the thesis needs confirmation from improving business or valuation signals.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for NVO come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for NVO. Last refresh: Oct 10, 2026, 10:30 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Novo Nordisk A/S does
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral…
Employees
66,700
Industry
Drug Manufacturers - General
Headquarters
Bagsvaerd, Denmark
What analysts expect
NVO carries a hold consensus from 12 analysts, with an average price target of $46.09 versus $38.64 today (+19.3%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
NVO generated $329.43B in trailing revenue (2.1% year over year), with a 35.3% net margin, and $37.67B of free cash flow, against $95.14B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $309.06B | $250.28B | $127.66B | $102.43B | $23.06 | $28.99B |
| 2024 | $290.40B | $245.88B | $128.34B | $100.99B | $22.67 | $69.66B |
| 2023 | $232.26B | $196.50B | $102.57B | $83.68B | $18.67 | $70.01B |
| 2022 | $176.95B | $148.51B | $74.81B | $55.52B | $12.26 | $64.13B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Famous investors who hold it
NVO is in the latest 13F of 1 of the 15 famous investors we follow. Renaissance Technologies (Founded by Jim Simons) holds the most of it: 0.20% of the portfolio, position #97 of 2,931, as of Q2 2026.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
NVO beside the healthcare names it is usually measured against.
What the chart is saying
In a downtrend, with $37.73 the next floor.
downtrend- Price is 11.0% below its 50-day average and 14.9% below its 200-day.
- The 50-day crossed below the 200-day on 2026-09-25 (a “death cross”).
- RSI at 38 is neither stretched nor washed out.
- The nearest ceiling is $39.58 (+2.4%), the nearest floor $37.73 (-2.4%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is NVO a good investment in 2026?
Novo Nordisk A/S trades at a P/E ratio of 9.4, with high volatility (34.6% annualized). Recent trend shows weakness.
What is the risk level of NVO?
Based on 30-day volatility of 34.6%, NVO has HIGH risk. Beta of 0.38 indicates lower sensitivity to market movements than average.
Does NVO pay dividends?
Yes, Novo Nordisk A/S has a dividend yield of 4.65%.
How far is NVO from its all-time high?
Novo Nordisk A/S is 73.9% below its all-time high of $148.15, reached in June 2024. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +130.3%, against +312.9% for the S&P 500 (SPY).
Which famous investors own NVO?
Renaissance Technologies (0.20% of Founded by Jim Simons's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for NVO?
The average analyst price target for Novo Nordisk A/S (NVO) is $46.09 based on 12 analyst estimates, about 19.3% above the current price of $38.64. The published range runs from $39.78 to $61.84.
How much revenue does NVO generate?
Novo Nordisk A/S reported $329.43B in trailing twelve-month revenue. Revenue growth is running at 2.1% year over year. Net margin sits at 35.3%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare NVO with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.